Palmitoylethanolamide (PEA) is a bioactive lipid mediator with anti-inflammatory, analgesic, and neuroprotective effects, helpful for managing chronic pain, neuropathic pain, and inflammation. It acts through PPAR-α activation, endocannabinoid modulation, mast cell stabilization, and neuroprotection. PEA reduces inflammation, enhances cannabinoid receptor effects by increasing anandamide, and modulates pain pathways like TRPV1 receptors. Aqueaux, an enhanced form of PEA using Aquasol technology, offers improved bio-accessibility and absorption, potentially increasing its effectiveness in conditions like allergic reactions, influenza, common cold, joint pain, psychopathologies, and neurodegeneration. In the pharmaceutical industry, it’s used in capsules, tablets, and sachets, while in nutraceuticals, it’s suitable for supplements and functional foods.